The sales of Renin-Angiotensin System medicines in Sweden were 860 million SEK in 2023. The forecasted sales show a steady increase from 2024 to 2028, with values rising from 905.3 million SEK in 2024 to 1090 million SEK in 2028. This indicates a consistent year-on-year growth rate, with the increases for each year as follows: 5.4% (2024), 5.4% (2025), 4.8% (2026), 5.0% (2027), and 3.8% (2028). The Compound Annual Growth Rate (CAGR) between 2024 and 2028 is approximately 4.9%.
Future trends to watch for include the impact of emerging competitors, potential advancements in related medical treatments, regulatory changes, and the overall economic environment which could influence healthcare spending and drug pricing.
